IRVINE, Calif., June 19, 2019 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) (Nasdaq: CYRXW) ("Cryoport" or the "Company") today announced the pricing of its underwritten public offering of an aggregate of 3,750,000 newly issued shares of common stock at a price...
Yesterday an article came out on Bloomberg that discussed the issues with reimbursement on Gilead's latest drug, Yescarta. For those who don't know, Yescarta is a CAR-T therapy that was developed by KITE Pharmaceuticals. CAR-T is the hottest space...
Tailwinds' Take: Dyadic is on a roll. The number of companies looking to license their technology is a resounding endorsement for C1. We expect to see more deals like this coming soon. JUPITER, FL / ACCESSWIRE / May 6, 2019...
Tailwinds' Take: There are currently no approved alternatives to vein harvesting and this study is the last step before applying to the FDA to begin human trials in a very large market. Results shouldn't take too long to be...
Tailwinds' Take: nice to see Vuzix and Upskill continuing to work together. Upskill has been a promoter of Google Glass, so we're appreciative of them being more vocal with VUZI, the industry leader in our opinion. Perhaps their customers...
Tailwinds' Take: as predicted by Derrick Zierler, Kopin comes out with a price point below $1,000. This is a game changer for the enterprise market and they should be able to take market share quickly. The space is growing...
IRVINE, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age, announced today fourth quarter and full year 2017 financial results. Results of operations for the three months ended Dec. 30, 2017 For the...
Tailwinds' Take: Very big news for Cryoport. McKesson is late to the regenerative therapy game and are trying to aggressively play catch-up with Cardinal Health (partners with Novartis and Gilead, but also using Cryoport in this capacity). As the...
SAN JOSE, Calif., Nov. 12, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that its two presentations at the 33rd Annual Meeting of The Society for...
Tailwinds Research was started with the simple goal of helping investors make money in micro-cap stocks. Over the last year and a half, there have been many successes and several missteps, but we’ve certainly accomplished our overall goal, generating...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.